Tech Company Financing Transactions
AXONIS Therapeutics Funding Round
Private investors participated in a $4 million Seed capital raise for AXONIS Therapeutics. The round was announced on 5/29/2020.
Transaction Overview
Company Name
Announced On
5/29/2020
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Seed
Investors
private investors (Lead Investor) (Kerry Murphy)
Proceeds Purpose
The funds will enable AXONIS to conduct pre-clinical studies on its novel technology that reactivates spared neural tissue at the spinal cord injury site through upmodulation of the KCC2 protein activity.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
AXONIS Therapeutics is advancing breakthrough drug discovery to develop groundbreaking therapies for spinal cord injury, and other currently incurable neurological disorders, making a real difference for patients, their families, and global healthcare system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joanna Stanicka
Chief Scientific Officer
Shane Hegarty
Browse more venture capital transactions:
Prev: 5/29/2020: Truth{set} venture capital transaction
Next: 5/29/2020: Stringr venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs